Open Access

MicroRNA‑139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression

Retraction in: /10.3892/ol.2022.13357

  • Authors:
    • Ying Ye
    • Juhua Zhuang
    • Guoyu Wang
    • Saifei He
    • Jing Ni
    • Wei Xia
  • View Affiliations

  • Published online on: October 17, 2017     https://doi.org/10.3892/ol.2017.7201
  • Pages: 7799-7806
  • Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Thyroid cancer is the most common tumour of the endocrine system, and its incidence rate has markedly increased over the past several decades. Aberrantly expressed microRNAs (miRNAs) are reportedly involved in the formation and progression of papillary thyroid carcinoma (PTC) by regulating their target genes. Thus, miRNAs may be potential molecular biomarkers for the prediction and prognosis of PTC, and also as novel therapeutic targets for patients with PTC. miR‑139 has recently been reported to be aberrantly expressed in several types of cancer. However, the expression levels, biological functions and the associated molecular mechanism of miR‑139 in PTC have not been clearly elucidated. The results of the present study revealed that miR‑139 expression was downregulated in PTC tissues and cell lines when compared with adjacent normal tissues and normal human thyroid cells, respectively. The restoration of miR‑139 expression suppressed cellular proliferation and invasion in PTC in vitro. In addition, fibronectin 1 (FN1) was identified as a direct target of miR‑139 in PTC. Furthermore, FN1 was highly expressed in PTC tissues and negatively associated with miR‑139 expression. Moreover, the tumour‑suppressive effects of miR‑139 overexpression on PTC cells were ameliorated by ectopic FN1 expression. To the best of our knowledge, the present study is the first to demonstrate that miR‑139 may serve as a tumour suppressor and serve important roles in inhibiting tumourigenesis by targeting FN1 in PTC cells.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ye Y, Zhuang J, Wang G, He S, Ni J and Xia W: MicroRNA‑139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression Retraction in /10.3892/ol.2022.13357. Oncol Lett 14: 7799-7806, 2017
APA
Ye, Y., Zhuang, J., Wang, G., He, S., Ni, J., & Xia, W. (2017). MicroRNA‑139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression Retraction in /10.3892/ol.2022.13357. Oncology Letters, 14, 7799-7806. https://doi.org/10.3892/ol.2017.7201
MLA
Ye, Y., Zhuang, J., Wang, G., He, S., Ni, J., Xia, W."MicroRNA‑139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression Retraction in /10.3892/ol.2022.13357". Oncology Letters 14.6 (2017): 7799-7806.
Chicago
Ye, Y., Zhuang, J., Wang, G., He, S., Ni, J., Xia, W."MicroRNA‑139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression Retraction in /10.3892/ol.2022.13357". Oncology Letters 14, no. 6 (2017): 7799-7806. https://doi.org/10.3892/ol.2017.7201